NCT02491229

"Hepafast" in Non-alcoholic Fatty Liver Disease (NAFLD)

Clinical Trial for Investigating the Effects of "Hepafast" on Non-alcoholic Fatty Liver Disease (NAFLD)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: University of Hohenheim · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate whether a weight reduction with "Hepafast" in combination with raw food and vegetables for two weeks followed by a meal substitution with "Hepafast" and a calorie restriction in accordance with the Low Glycemic and Insulinemic Diet (LOGI) for 10 weeks is superior regarding improvement of non-alcoholic Fatty Liver Disease (NAFLD) compared to a conventional weight reduction in accordance with the LOGI diet without use of "Hepafast" for 12 weeks.

Conditions

• Non-alcoholic Fatty Liver Disease (NAFLD)
• Obesity

Interventions

Type	Name	Description
OTHER	Hepafast	Two weeks of Hepafast three times a day and additionally 200 kcal followed by 10 weeks of Hepafast two times a day and a meal according to LOGI diet
OTHER	LOGI diet	For twelve weeks, this group eats meals according to the Low Glycemic and Insulinemic Diet (LOGI).

Timeline

• Start date: 2015-01-01
• Primary completion: 2015-05-01
• Completion: 2015-12-01
• First posted: 2015-07-07
• Last updated: 2016-01-14

Locations

1 site across 1 country: Germany